Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA

Core Viewpoint - Levi & Korsinsky, LLP has initiated a class action securities lawsuit on behalf of investors in Cassava Sciences, Inc. due to alleged securities fraud impacting the company's stock performance [2][3]. Group 1: Lawsuit Details - The lawsuit targets losses incurred by Cassava Sciences, Inc. investors from February 7, 2024, to November 24, 2024, related to alleged securities fraud [3]. - The complaint alleges that defendants misled investors regarding the efficacy of Cassava's drug candidate, simufilam, particularly in treating Alzheimer's Disease [4]. - Following the release of disappointing Phase 3 study results for simufilam on November 25, 2024, the stock price plummeted from $26.48 to$4.30, marking a decline of approximately 83.76% in one day [4]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 10, 2025, to request appointment as lead plaintiff in the lawsuit [5]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [5].